PLASMA HOMOCYST (E) INE CONCENTRAT IS ASSOCIAT W/ VARIATION IN CAROTID PLAQUE ARE
血浆同型半胱氨酸 (E) 浓缩物与颈动脉斑块的变化有关
基本信息
- 批准号:6312910
- 负责人:
- 金额:$ 10.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1978
- 资助国家:美国
- 起止时间:1978-05-01 至 2004-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In primates, treatment with antiprogestins including RU 486 and ZK
137 316 will both block progesterone (P) action, and also inhibit
estrogen stimulated proliferation in the endometrium. This action of
antiprogestins would be of benefit to women treated with estrogen
replacement therapy as a method of blocking untoward effects of
estrogen on the endometrium. ZK 230 211 (ZK211) is a potent new
generation antiprogestin produced by Schering AG, that can be
administered both orally and systemically. The goal of this research
was to determine if ZK211 will inhibit the proliferative actions of
estrogen delivered continuously for 5 months. Six groups of rhesus
macaques (n = 5 each) were treated with estradiol (E2)-filled implants
for 5 months. Three of the groups were also injected daily with 3
different doses of ZK211 (0. 01, 0.05 and 0.25 mg/kg). P is known to
oppose the proliferative action of E2 in the endometrium. Therefore,
for comparison, 1 group received E2 plus a low dose of P (2 cm P
implants) and one group received E2 plus a high dose of P (6 cm P
implants). Control animals (group 6) received estrogen alone.
Treatment with ZK211 resulted in a severe reduction of endometrial
mass, which was associated with a dose dependent inhibition of
epithelial cell proliferation. At higher doses of ZK211, this effect
resulted in the upper portions of the glands degenerating and trapping
secretory material. These higher doses led to formation of moderate
size endometrial cysts, which appeared to contain trapped secretory
material. There was no evidence of endometrial hyperplasia or
metaplasia. As anticipated, long-term E2 + P treatment resulted in a
dose-dependent decidualization response that was marked by extensive
spiral artery hypertrophy. This effect on the spiral arteries was
opposite to the reaction to that seen with ZK 211 which inhibited
vascular development. We conclude that inhibition of vascular
development by ZK 211 may be the key factor underlying the
degenerative inhibition and blockade of estrogen-dependent endometrial
proliferation induced by this antiprogestin. FUNDING Contract with
Schering AG, Berlin, Germany PUBLICATIONS None
在灵长类动物中,使用包括RU 486和ZK在内的抗孕激素治疗
137 316既能阻断孕酮(P)的作用,也能抑制
雌激素刺激子宫内膜增殖。 的这个动作
抗孕激素对接受雌激素治疗的妇女有益
替代疗法作为一种阻断
子宫内膜上的雌激素 ZK 230 211(ZK 211)是一种强大的新型
由Schering AG生产的第二代抗胰蛋白酶素,其可以是
口服和全身给药。 本研究的目的
是为了确定ZK 211是否会抑制
雌激素连续给药5个月。 六组恒河猴
用雌二醇(E2)填充的植入物处理猕猴(每种n = 5
五个月 其中三组也每天注射3
ZK211(0. 01、0.05和0.25 mg/kg)。 P已知
对抗E2在子宫内膜中的增殖作用。 因此,我们认为,
作为对照,1组接受E2加低剂量P(2cm P
一组接受E2加高剂量P(6 cm P
植入物)。 对照动物(第6组)仅接受雌激素。
ZK 211治疗导致子宫内膜严重减少,
质量,这与剂量依赖性抑制有关,
上皮细胞增殖 在较高剂量的ZK 211下,这种效应
导致腺体的上部退化并陷入
分泌物质 这些较高的剂量导致形成中度
大小的子宫内膜囊肿,其中似乎包含被困分泌
材料 没有子宫内膜增生的证据,
化生 正如预期的那样,长期E2 + P治疗导致了
剂量依赖性蜕膜化反应,其特征是广泛的
螺旋动脉肥大 这种对螺旋动脉的影响是
与ZK 211所见的反应相反,ZK 211抑制了
血管发育 我们的结论是,抑制血管
ZK 211的发展可能是潜在的关键因素
雌激素依赖性子宫内膜的退行性抑制和阻断
由这种抗胰蛋白酶素诱导的增殖。 融资合同
Schering AG,柏林,德国出版物无
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN Charles SPENCE其他文献
JOHN Charles SPENCE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN Charles SPENCE', 18)}}的其他基金
TRD4: Design and Engineering of MicroED hardware for nanocrystallization and time resolved studies
TRD4:用于纳米结晶和时间分辨研究的 MicroED 硬件的设计和工程
- 批准号:
10155530 - 财政年份:2020
- 资助金额:
$ 10.1万 - 项目类别:
TRD4: Design and Engineering of MicroED hardware for nanocrystallization and time resolved studies
TRD4:用于纳米结晶和时间分辨研究的 MicroED 硬件的设计和工程
- 批准号:
10641827 - 财政年份:2020
- 资助金额:
$ 10.1万 - 项目类别:
TRD4: Design and Engineering of MicroED hardware for nanocrystallization and time resolved studies
TRD4:用于纳米结晶和时间分辨研究的 MicroED 硬件的设计和工程
- 批准号:
10460925 - 财政年份:2020
- 资助金额:
$ 10.1万 - 项目类别:
IMAGING NANO-SIZED HOLES ON SURFACE OF PORETICS POLYCARBONATE SCREEN MEMBRANES
对 PORITICS 聚碳酸酯丝网膜表面的纳米孔进行成像
- 批准号:
7183096 - 财政年份:2005
- 资助金额:
$ 10.1万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 10.1万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 10.1万 - 项目类别: